Login
Navigate Fool.com
Will ALIM beat
the market?
Community Rating: 1 Star: Ominous

6.31 0.01 (0.16%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $6.25
Previous Close $6.30
Daily Range $6.06 - $6.48
52-Week Range $1.65 - $8.44
Market Cap $239.2M
P/E Ratio -3.90
Dividend (Yield) $0.00 (0.0%)
Volume 153,053
Average Daily Volume 290,411
Current FY EPS -$1.11

How do you think ALIM
will perform against the market?

Top ALIM Bull/Bear Pitches

 

TSIF (< 20)
Submitted November 13, 2011

Alimera Sciences, Inc got the dreaded &quot;complete response letter&quot; from the FDA, meaning that it's drug approval under consideration was denied. These can come in several forms. A hard kill … More

0 Replies Reply Report this Post
 

zzlangerhans (< 20)
Submitted December 14, 2011

I'm somewhat obligated to keep tracking Alimera on CAPS, if for no reason other than to take my mea culpa on recommending it (and buying it) prior to their horrendous PDUFA faceplant last month. I've … More

0 Replies Reply Report this Post

News & Commentary

Today’s Top Biotech Stories: Lexicon, Alimera, and Akebia

Lexicon, Alimera, and Akebia are the top stories to watch in the biotech sector this Monday morning.

Why AK Steel, Idenix Pharmaceuticals, and Alimera Sciences Are Today's 3 Best Stocks

The S&P 500 breaks a three-day losing streak as AK Steel, Idenix Pharmaceuticals, and Alimera Sciences all rocket higher by double-digits.

3 Biggest Winners in Biotech Last Week

What were the biggest movers in biotech last week?

Healthcare Stocks Closing Lower; Opko Sells Sorrento Therapeutics Stake For 10-Fold Gain on 2009 Inv

Healthcare Stocks Closing Lower; Opko Sells Sorrento Therapeutics Stake For 10-Fold Gain on 2009 Investment

Sector Update: Healthcare

pSivida, Alimera and Ariad Join Bio-Implosion Watch

Five FDA Approvals and Reviews at Risk Under a Government Shutdown

Trade the Earnings: Alimera Sciences, Inc.

After-Hours Earnings Report for March 21, 2013 : NKE, SLW, MU, TIBX, RUE, NWY, ALIM

After-Hours Earnings Report for March 21, 2013 : NKE, SLW, MU, TIBX, RUE, NWY, ALIM

Buy, Sell, or Hold: MannKind

Do the potential benefits here outweigh the risks?

See More ALIM News...

Sector

Healthcare

Industry

Drugs

Alimera Sciences, Inc. (ALIM) Description

Alimera Sciences Inc. is a biopharmaceutical company that engaged in the research development and commercialization of ophthalmic pharmaceuticals. Website: http://www.alimerasciences.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks